Virax Biolabs GroupVRAX
13F holders, Q2 2025 (June 30)2holders −2
1new positions
3sold out
1famous investor
$0.81avg. 13F price*
At the end of Q2 2025, 2 institutions reported holding Virax Biolabs Group Ltd. (VRAX) in their 13F filings, down 2 from Q1 2025. 1 opened new positions and 3 sold out. The largest holders were Citadel Advisors ($25K) and National Bank of Canada ($4K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Virax Biolabs Group Ltd.
- CUSIP
- G9495L125
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $4K |
| Exits | 3 | $56K |
All 13F filers, Q1 2025 → Q2 2025: 21,616 shares bought and 49,559 shares sold, net −27,943 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| Citadel Advisors | 0.00% | Add +122.7% | 30,155 | $25K |
| National Bank of Canada | 0.00% | New | 5,000 | $4K |
"% of holder's portfolio" is VRAX's weight in each manager's 13F, not the share of Virax Biolabs Group Ltd. the manager owns.